Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Multisystem
100%
Immune-related Adverse Events
100%
Immune Checkpoint Inhibitors
100%
IrAE
54%
Overall Survival
27%
Thyroiditis
27%
Anti-PD-1
27%
Multivariable Model
18%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
18%
Adjusted Odds Ratio
18%
Programmed Death-ligand 1 (PD-L1)
18%
Pneumonitis
18%
Monotherapy
18%
Dermatitis
18%
Odds Ratio
9%
Retrospective Cohort Study
9%
Risk Factors
9%
Patient Survival
9%
Multivariable Logistic Regression
9%
Kaplan-Meier Method
9%
Tumor Subtype
9%
Organ System
9%
Patients Included
9%
Adjusted Hazard Ratio
9%
Independent Risk Factors
9%
Multicenter Cohort Study
9%
Hepatitis
9%
Stage III-IV
9%
Improved Survival
9%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
9%
Anticancer Agents
9%
Progression-free
9%
Median Range
9%
Survival Factor
9%
Event-based Systems
9%
Immune Checkpoint Inhibitor Monotherapy
9%
Immune Checkpoint Inhibitor Combinations
9%
Medicine and Dentistry
Immune-Related Adverse Events
100%
Treatment of Non-Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Odds Ratio
27%
Non Small Cell Lung Cancer
27%
Overall Survival
27%
Monotherapy
27%
Thyroiditis
27%
Pneumonia
18%
Programmed Cell Death
18%
Oncology
18%
Dermatitis
18%
Neoplasm
9%
Logistic Regression Analysis
9%
Retrospective Cohort Study
9%
Cohort Analysis
9%
Hazard Ratio
9%
Kaplan Meier Method
9%
Organ Systems
9%
Anticarcinogen
9%
Progression Free Survival
9%